Actively Recruiting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-09-25
172
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital of Zhejiang University
Lead Sponsor
Z
Zhejiang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.
CONDITIONS
Official Title
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with deep venous thrombosis (DVT) and ipsilateral iliac vein stenosis greater than 50% caused by iliac vein compression or remaining thrombus after thrombectomy
- Patients who have undergone percutaneous mechanical thrombectomy (PMT) with or without catheter directed thrombolysis (CDT) to reduce thrombus
- Patients who have received iliac venous stent implantation within 30 days after PMT or CDT
You will not qualify if you...
- Chronic DVT or DVT onset longer than 3 weeks
- Isolated distal DVT not affecting ipsilateral femoral or iliac vein
- Glomerular filtration rate less than 60 ml/min
- Ipsilateral varicose veins or venous insufficiency before DVT, including skin pigmentation, edema, lipodermatosclerosis, or venous ulcer
- Acute arterial embolism or moderate or greater stenosis in abdominal aorta, ipsilateral iliac artery, or lower extremity artery
- Known aneurysms or limiting dissection in abdominal aorta, ipsilateral iliac artery, or lower extremity artery
- Contraindications to antiplatelet or anticoagulant drugs
- Untreatable systemic diseases
- Prior use of anticoagulants or antiplatelet drugs before DVT
- Under 18 years old or refusal to join the study
- Myocardial infarction within past 6 months
- High bleeding risk due to history of brain hemorrhage or stroke, gastrointestinal bleeding or pathology, liver failure, bleeding disorders, extreme old age or frailty, or severe kidney failure requiring dialysis or eGFR below 15 ml/min/1.73 m2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affliated Hospital, Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
H
Hongkun Zhang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here